Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-Label, Study of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Human Immunodeficiency Virus/Genotype 1 Chronic Hepatitis C Coinfected Subjects With Severe Fibrosis or Compensated Cirrhosis

NCT01500616 is registered in ClinicalTrials.gov with Janssen-Cilag International NV as lead sponsor.

NCT NCT01500616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01500616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-Label, Study of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Human Immunodeficiency Virus/Genotype 1 Chronic Hepatitis C Coinfected Subjects With Severe Fibrosis or Compensated Cirrhosis
Lead sponsor
Janssen-Cilag International NV
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2012
Completion date
August 31, 2014
Enrollment
122 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic